INTRODUCTION {#s1}
============

An estimated 455 800 and 527 600 new cases and 400 200 and 265 700 deaths related to esophageal and cervical cancer, respectively, have been reported worldwide \[[@R1]\]. Notably, postoperative recurrences occur in approximately half of all patients with esophageal squamous cell carcinoma (ESCC) \[[@R2]\], and it is the third leading cause of cancer deaths among women in developing countries \[[@R1]\]. Additionally, an estimated 1.8 million new lung cancer cases have occurred worldwide, accounting for approximately 13% of all cancers \[[@R1]\]. Therefore, the early detection of such malignancies is urgently necessary.

The melanoma inhibitory activity (*MIA*) gene family includes MIA, MIA2, Transport and Golgi organization protein 1 (TANGO), and otoraplin (OTOR). Members of this family share 34%--45% amino acid homology and 47%--59% cDNA sequence homology and feature a highly conserved SH3-like domain and hydrophobic N-terminal secretory signal sequences \[[@R3]--[@R6]\]. Although OTOR expression is highly restricted to healthy eyes, cochlea, and cartilage \[[@R7]\], other members of the *MIA* gene family have several tumor-related functions. MIA expression correlates with cancer cell detachment, migration, invasion, and apoptotic repression and is accordingly related to malignant tumor progression, metastasis, and poor prognosis \[[@R8]--[@R12]\]. MIA2 is induced in liver fibrosis or cirrhosis by activating transforming growth factor-beta (TGF-β) signaling \[[@R13], [@R14]\] and serves as a tumor suppressor in liver cancers following the loss of hepatocyte nuclear factor-1 (HNF-1) expression \[[@R15]\]. However, wild-type MIA2 promotes the loss of chemosensitivity in pancreatic cancers, thus worsening an already poor prognosis \[[@R16]\]. Regarding other *MIA* gene family members, TANGO has been suggested as a tumor suppressor in malignant melanoma, colorectal cancer, and hepatoma \[[@R4], [@R6]\]. In summary, the functions of *MIA* gene family members in malignancies have not been well documented.

We previously reported that *MIA* gene family members act as oncogenes in oral squamous cell carcinoma (OSCC) \[[@R17]--[@R20]\]. For example, MIA expression is enhanced by high-mobility group box 1 (HMGB1) nuclear factor kappa B (NFkB) p65 complexes that bind to the *MIA* promoter region, thus promoting tumor progression, nodal metastasis, a worse prognosis, angiogenesis, and lymphangiogenesis through the upregulation of vascular endothelial growth factor (VEGF)-A, VEGF-C, and VEGF-D expression \[[@R17], [@R18]\]. MIA2 activates MAPK p38, c-Jun N-terminal kinase (JNK), and VEGF family members through its receptors, integrin α~4~β~1~ and α~5~β~1~ \[[@R19]\]. MIA2 expression is also associated with local expansion, nodal metastasis, and inhibited host anti-cancer immunity and apoptosis in OSCC \[[@R19]\]. Furthermore, TANGO promotes angiogenesis and lymphangiogenesis by upregulating platelet-derived growth factor beta polypeptide (PDGFB) and neuropilin 2 in OSCC \[[@R20]\].

Tumor biomarkers have been classified as screening (used diagnostically to identify patients), staging (used to stage disease), prognostic (used to predict outcome), and predictive and monitoring markers (used to speculate and observe clinical responses to any treatment) \[[@R21], [@R22]\]. Cancer biomarkers must also satisfy the following conditions: (1) the transition can be objectively determined the quality; (2) must be measureable in small sample amounts; (3) must be altered in tumors but not in normal tissues; and (4) must be altered at an early phase of cancer development \[[@R22], [@R23]\]. However, the role of MIA gene family as tumor markers in various human malignancies remains controversial. The purpose of this study was to investigate the usefulness of *MIA* gene family as novel tumor markers in various human neoplastic specimens, including ESCC, lung cancer, and cervical cancer.

RESULTS {#s2}
=======

Screening for MIA gene family expression in human tumors {#s2_1}
--------------------------------------------------------

We initially used immunohistochemistry to examine the expression of *MIA* gene family members in 477 cases of different tumors. The specificity of the antibodies for *MIA* gene family was confirmed by Western blotting with recombinant proteins (data not shown). These results are summarized in Table [1](#T1){ref-type="table"}. Briefly, higher MIA, MIA2, and TANGO expression levels were observed in 80 (16.8%), 67 (14.1%), and 76 (15.9%) of these cases, respectively. All immunopositive cases exhibited cytoplasmic *MIA* gene family staining. Several representative images of *MIA* gene family immunostaining in tumors are shown in Figure [1A](#F1){ref-type="fig"} to [1I](#F1){ref-type="fig"}.

###### Expression of MIA gene family in human tumors

                                                      Number of overexpression cases               
  ---------------------------------------------- ---- -------------------------------- ----------- ------------
  Head and neck (oral cavity, larynx, pharynx)                                                     
   Squamous cell carcinoma                       30   13 (43.3%)                       12 (40%)    10 (33.3%)
   Others                                        6    0 (0%)                           0 (0%)      0 (0%)
  Salivary gland                                                                                   
   Acinic cell carcinoma                         3    0 (0%)                           0 (0%)      1 (33.3%)
   Adenoid cystic carcinoma                      3    1 (33.3%)                        1 (33.3%)   1 (33.3%)
   Mucoepidermoid carcinoma                      2    0 (0%)                           0 (0%)      0 (0%)
   Others                                        7    1 (14.3%)                        0 (0%)      0 (0%)
  Esophagus                                                                                        
   Squamous cell carcinoma                       10   4 (40%)                          4 (40%)     4 (40%)
  Stomach                                                                                          
   Adenocarcinoma                                35   10 (28.6%)                       5 (14.3%)   6 (17.1%)
  Small intestine                                                                                  
   Gastrointestinal stromal tumor                5    0 (0%)                           0 (0%)      0 (0%)
  Colorectum                                                                                       
   Adenocarcinoma                                35   11 (31.4%)                       6 (17.1%)   8 (22.9%)
  Liver                                                                                            
   Hepatocellular carcinoma                      16   0 (0%)                           7 (43.8%)   3 (18.8%)
  Biliary system                                                                                   
   Adenocarcinoma                                10   1 (10%)                          2 (20%)     1 (10%)
  Pancreas                                                                                         
   Adenocarcinoma                                5    0 (0%)                           2 (40%)     1 (20%)
  Lung                                                                                             
   Squamous cell carcinoma                       18   6 (33.3%)                        5 (27.8%)   6 (33.3%)
   Adenocarcinoma                                11   2 (18.2%)                        2 (18.2%)   2 (18.2%)
   Others                                        4    0(0%)                            0 (0%)      0 (0%)
  Soft tissue                                                                                      
   Liposarcoma                                   12   0 (0%)                           0 (0%)      0 (0%)
   Undifferentiated pleomorphic sarcoma          4    0 (0%)                           0 (0%)      0 (0%)
   Others                                        9    0 (0%)                           0 (0%)      0 (0%)
  Bone                                                                                             
   Chondrosarcoma                                8    4 (50%)                          0 (0%)      0 (0%)
   Osteosarcoma                                  3    0 (0%)                           0 (0%)      0 (0%)
   Others                                        5    0 (0%)                           0 (0%)      0 (0%)
  Skin                                                                                             
   Malignant melanoma                            10   6 (60%)                          2 (20%)     2 (20%)
   Squamous cell carcinoma                       3    1 (33.3%)                        1 (33.3%)   1 (33.3%)
  Breast                                                                                           
   Invasive ductal carcinoma                     7    2 (28.6%)                        0 (0%)      3 (42.9%)
   Invasive lobular carcinoma                    4    0 (0%)                           1 (25%)     1 (25%)
   Others                                        8    0 (0%)                           0 (0%)      0 (0%)
  Uterine cervix                                                                                   
   Squamous cell carcinoma                       21   8 (38.1%)                        6 (28.6%)   7 (33.3%)
   Others                                        5    0 (0%)                           0 (0%)      0 (0%)
  Endometrium                                                                                      
   Endometrioid adenocarcinoma                   11   0 (0%)                           3 (27.3%)   3 (27.3%)
   Others                                        1    0 (0%)                           0 (0%)      0 (0%)
  Ovary                                                                                            
   Serous adenocarcinoma                         11   2 (18.2%)                        1 (9.1%)    2 (18.2%)
   Mucinous adenocarcinoma                       8    0 (0%)                           1 (12.5%)   1 (12.5%)
   Endometrioid adenocarcinoma                   5    1 (20%)                          0 (0%)      1 (20%)
   Clear cell carcinoma                          4    0 (0%)                           0 (0%)      0 (0%)
   Dysgerminoma                                  4    0 (0%)                           0 (0%)      1 (25%)
   Others                                        15   1 (6.7%)                         0 (0%)      0 (0%)
  Prostate                                                                                         
   Adenocarcinoma                                6    2 (33.3%)                        0 (0%)      2 (33.3%)
  Testis                                                                                           
   Seminoma                                      8    2 (25%)                          0 (0%)      2 (25%)
   Others                                        3    0 (0%)                           0 (0%)      0 (0%)
  Urinary bladder                                                                                  
   Urothelial carcinoma                          17   2 (11.8%)                        1 (5.9%)    3 (17.7%)
  Kidney                                                                                           
   Renal cell carcinoma                          13   0 (0%)                           5 (38.5%)   0 (0%)
   Others                                        3    0 (0%)                           0 (0%)      0 (0%)
  Thyroid                                                                                          
   Papillary carcinoma                           12   0 (0%)                           0 (0%)      4 (33.3%)
   Others                                        3    0 (0%)                           0 (0%)      0 (0%)
  Adrenal gland                                                                                    
   Cortical carcinoma                            10   0 (0%)                           0 (0%)      1 (10%)
   Pheochromocytoma                              3    0 (0%)                           0 (0%)      0 (0%)
   Others                                        2    0 (0%)                           0 (0%)      0 (0%)
  Lymphoid tissue                                                                                  
   Malignant lymphoma                            20   0 (0%)                           0 (0%)      0 (0%)
   Other tissues                                 19   0 (0%)                           0 (0%)      0 (0%)

![Expression of *MIA* gene family in human tumors\
(**A--C**) Immunostaining of MIA in human tumors. Cytoplasmic expression of MIA was detected in chondrosarcoma of the bone (A), invasive ductal carcinoma of the breast (B), and seminoma of the testis (C). (**D--F**) Immunostaining of MIA2 in human tumors. Cytoplasmic localization of MIA2 was found in colonic adenocarcinoma (D), pancreatic adenocarcinoma (E), and renal cell carcinoma (F). (**G--I**) Immunostaining of TANGO in human tumors. Cytoplasmic staining of TANGO was observed in endometrial endometriod adenocarcinoma (G), ovarian serous cystadenocarcinoma (H), and papillary carcinoma of the thyroid (I). Original magnification, 400 fold.](oncotarget-07-31137-g001){#F1}

MIA overexpression was observed in 13 of 30 head and neck SCCs (43.3%), 4 of 10 ESCCs (40%), 10 of 35 gastric adenocarcinomas (28.6%) (Figure [1A](#F1){ref-type="fig"}), 11 of 35 colorectal adenocarcinomas (31.4%), 6 of 18 lung SCCs (33.3%), 1 of 3 cutaneous SCCs (33.3%), 2 of 7 mammary invasive ductal carcinomas (28.6%) (Figure [1B](#F1){ref-type="fig"}), 8 of 21 cervical SCCs (38.1%), 2 of 6 prostatic adenocarcinomas (33.3%), and 2 of 8 testicular seminomas (25%) (Figure [1C](#F1){ref-type="fig"}). Twelve of the 30 head and neck SCCs (40%), 3 of 10 ESCCs (30%), 7 of 16 hepatocellular carcinomas (43.8%), 2 of 5 pancreatic adenocarcinomas (40%) (Figure [1E](#F1){ref-type="fig"}), 5 of 18 lung SCCs (27.8%), 2 of 10 cutaneous malignant melanomas (20%), 1 of 3 cutaneous SCCs (33.3%), 6 of 21 cervical SCCs (28.6%), 3 of 11 endometrial endometrioid adenocarcinomas (27.3%), and 5 of 13 renal cell carcinoma (38.5%) (Figure [1F](#F1){ref-type="fig"}) exhibited excessive MIA2 immunoreactivity. Elevated TANGO expression levels were detected in 10 of 30 head and neck SCCs (33.3%), 3 of 10 ESCCs (30%), 8 of 35 colorectal adenocarcinomas (22.9%), 1 of 5 pancreatic adenocarcinomas (20%), 6 of 18 lung SCCs (33.3%), 2 of 10 cutaneous malignant melanomas (20%), 1 of 3 cutaneous SCCs (33.3%), 3 of 7 mammary invasive ductal carcinomas (32.9%), 7 of 21 cervical SCCs (33.3%), 3 of 11 endometrial endometrioid adenocarcinomas (27.3%) (Figure [1G](#F1){ref-type="fig"}), 2 of 6 prostatic adenocarcinomas (33.3%), 2 of 8 testicular seminomas (25%), and 4 of 12 papillary thyroid carcinomas (33.3%) (Figure [1I](#F1){ref-type="fig"}). MIA2 and TANGO immunostaining in a colonic adenocarcinoma and ovarian serous adenocarcinoma are shown in Figure [1D and 1H](#F1){ref-type="fig"}, respectively. Overall, SCCs were more likely to express *MIA* gene family members. Detailed MIA, MIA2, and TANGO immunohistochemistry results in other human malignant tumors are presented in Table [1](#T1){ref-type="table"}.

We formerly reported that MIA, MIA2, and TANGO act as oncogenes in OSCC \[[@R17]--[@R20]\]; however, the significance of *MIA* gene family expression in SCCs of other organs, such as the esophagus, cervix, and lung, has not been clarified. Accordingly, we next inspected the relationship between *MIA* gene family immunostaining and clinicopathological features in those malignancies.

Relationship MIA gene family expression and clinicopathological parameters in esophageal cancers {#s2_2}
------------------------------------------------------------------------------------------------

Compared with non-tumor esophageal epithelium, ESCC tissues were more likely to exhibit subcellular *MIA* gene family expression. MIA, MIA2, and TANGO overexpression was detected in 33.3% (22/66), 30.3% (20/66), and 27.3% (18/66) of ESCC cases, respectively (Figure [2A--2C](#F2){ref-type="fig"}). Further, co-expression rate of MIA and MIA2, MIA and TANGO, MIA2 and TANGO, and all molecules were 15.2% (10/66), 16.7% (11/66), 13.6% (9/66), and 9.1% (6/66), respectively. The correlations between *MIA* gene family expression and clinicopathological parameters are summarized in Table [2](#T2){ref-type="table"}. MIA upregulation correlated only with nodal metastasis, and 15 of 32 (46.9%) patients with nodal metastasis exhibited MIA immunopositivity (*P* = 0.0362). On the other hand, MIA2 expression correlated significantly with the clinical stage (*P* = 0.0026), local tumor cell progression (T classification; *P* = 0.0076), and nodal metastasis (*P* = 0.0069). Furthermore, TANGO expression was observed in 14 of 32 (43.8%) and 9 of 13 (69.2%) cases involving nodal or distant metastasis, respectively, with lower rates among patients with no nodal progression (4/34, 11.8%; *P* = 0.0053) or distant metastasis (9/53, 17%; *P* = 0.0005). No strong relationships of MIA, MIA2, or TANGO expression with other clinicopathological characteristics were found in ESCC cases.

![Immunostaining of the *MIA* gene family in esophageal cancer\
(**A--C**) Immunohistochemistry of the *MIA* gene family in human ESCC. Immunostaining of MIA (A), MIA2 (B), and TANGO (C) was detected in the cytoplasm of ESCC cells. Original magnification, 400 fold. ESCC: esophageal squamous cell carcinoma.](oncotarget-07-31137-g002){#F2}

###### Relationship between expression of MIA gene family and clinicopathological characteristics in ESCC

                                                                    MIA      MIA2     TANGO                  
  ----------------------------------------------------------------- -------- -------- -------- ---- -------- ----
  Gender                                                                                                     
  Male                                                              31       18       37       12   34       15
   Female                                                           13       4        9        8    14       3
   *P* value                                                        0.3836            0.1244        0.3614   
  Age                                                                                                        
   \< −65                                                           14       8        13       9    17       5
   \> 65                                                            30       14       33       11   31       13
   *P* value                                                        0.7848            0.2565        0.7702   
  Alcohol intake                                                                                             
   Habitual drinking                                                24       16       25       15   26       14
   Social drinking                                                  14       6        16       4    16       4
   No drinking                                                      6        0        5        1    6        0
   *P* value                                                        0.1423            0.2844        0.1362   
  Histological differentiation[\*](#tfn_001){ref-type="table-fn"}                                            
   Well                                                             23       14       25       12   26       11
   Mod, Por                                                         21       8        21       8    22       7
   *P* value                                                        0.4381            0.7894        0.7817   
  Clinical stage                                                                                             
   I--II                                                            25       9        28       6    28       6
   III--IV                                                          19       13       18       14   20       12
   *P* value                                                        0.2978            0.0317        0.0983   
  T classification                                                                                           
   T1--2                                                            22       8        26       4    24       6
   T3--4                                                            22       14       20       16   24       12
   *P* value                                                        0.4320            0.0076        0.2748   
  Nodal metastasis                                                                                           
   Negative                                                         27       7        29       5    30       4
   Positive                                                         17       15       17       15   18       14
   P value                                                          0.0362   0.0069   0.0053                 
  Distant metastasis                                                                                         
   Negative                                                         37       16       38       15   44       9
   Positive                                                         7        6        8        5    4        9
   *P* value                                                        0.3313            0.5117        0.0005   

Relationship between expression of MIA gene family and parameters were calculated by Fischer\'s exact test. T classification and clinical stage were classified according to the TNM classification.

Histological differentiation: Well, well-differentiated squamous cell carcinoma; Mod, moderately differentiated squamous cell carcinoma; Por, poorly differentiated squamous cell carcinoma.

Association between MIA gene family expression and clinicopathological characteristics in lung cancers {#s2_3}
------------------------------------------------------------------------------------------------------

A summary of the results pertaining to lung cancer is shown in Table [3](#T3){ref-type="table"}. Non-cancerous lungs did not overexpress *MIA* gene family members; in contrast, cytoplasmic MIA, MIA2, and TANGO expression was found in 49 (33.8%), 45 (31%) and 47 (32.4%) of the 145 cases, respectively (Figure [3A--3F](#F3){ref-type="fig"}). Additionally, co-expression rate of MIA and MIA2, MIA and TANGO, MIA2 and TANGO, and all molecules were 24.8% (36/145), 17.2% (25/145), 19.3% (28/145), and 13.8% (20/145), respectively. Strong MIA, MIA2, and TANGO immunoreactivity levels were detected in 41% (43/105), 37.1% (39/105), and 40% (42/105) of SCCs, respectively; notably, the MIA, MIA2, and TANGO expression frequencies in adenocarcinomas, small cell carcinomas, and LCNECs were significantly lower than those in SCCs (Figure [3A--3F](#F3){ref-type="fig"}; *P* = 0.0307, *P* = 0.0453, and *P* = 0.0173, respectively). Higher MIA (21/36, 58.3%), MIA2 (19/36, 52.8%), and TANGO expression levels (21/36, 58.3%) were observed in cases with nodal metastasis relative to those without lymph node involvement (*P* = 0.0005, *P* = 0.0018, and *P* = 0.0004, respectively). MIA and MIA2 expression also correlated with distant metastasis; 11 of 17 (64.7%) patients with distant metastases exhibited MIA and MIA2 immunopositivity (*P* = 0.0063 and *P* = 0.0036, respectively). Moreover, TANGO expression correlated significantly with the T classification (*P* = 0.0177). There were no significant relationships between MIA gene family expression and other clinicopathological parameters in lung cancers.

###### Relationship between expression of MIA gene family and clinicopathological characteristics in lung cancer

                                                  MIA      MIA2   TANGO                  
  ----------------------------------------------- -------- ------ -------- ---- -------- ----
  Gender                                                                                 
   Male                                           69       38     71       36   69       38
   Female                                         27       11     29       9    29       9
   *P* value                                      0.5512          0.3101        0.2276   
  Age                                                                                    
   \< −65                                         47       20     49       18   47       20
   \> 65                                          49       29     51       27   51       27
   *P* value                                      0.3827          0.3696        0.5957   
  Smoking habit                                                                          
   Yes                                            63       39     67       35   64       38
   No                                             33       10     33       10   34       9
   *P* value                                      0.0879          0.2394        0.0796   
  Histology [\*](#tfn_002){ref-type="table-fn"}                                          
   SCC                                            62       43     66       39   63       42
   Adeno                                          21       4      20       5    22       3
   Small                                          9        1      10       0    9        1
   LCNEC                                          4        1      4        1    4        1
   *P* value                                      0.0307          0.0453        0.0173   
  Clinical stage                                                                         
   I                                              18       13     24       8    26       6
   II                                             43       20     42       21   45       18
   III--IV                                        34       16     34       16   27       23
   *P* value                                      0.5766          0.6971        0.0252   
  T classification                                                                       
   T1                                             19       13     24       8    26       6
   T2                                             38       18     36       20   41       15
   T3--4                                          39       18     40       17   31       26
   *P* value                                      0.6503          0.5609        0.0177   
  Nodal metastasis                                                                       
   Negative                                       81       28     83       26   83       26
   Positive                                       15       21     17       19   15       21
   *P* value                                      0.0005          0.0018        0.0004   
  Distant metastasis                                                                     
   Negative                                       90       38     94       34   87       41
   Positive                                       6        11     6        11   11       6
   *P* value                                      0.0063          0.0036        0.7876   

Relationship between expression of MIA gene family and parameters were calculated by Fischer\'s exact test or chi-square test. T classification and clinical stage were classified according to the TNM classification.

Histology: SCC, squamous cell carcinoma; adeno, adenocarcinoma; small, small cell carcinoma; LCNEC, large cell neuroendocrine cell carcinoma.

![Expression of the *MIA* gene family in lung cancer\
(**A--C**) Immunohistochemical analysis of the *MIA* gene family in adenocarcinoma. Expression of MIA (A), MIA2 (B), and TANGO (C) was not detected in lung adenocarcinoma. (**D--F**) Immunohistochemistry of the *MIA* gene family in SCC. Cytoplasmic localization of MIA (D), MIA2 (e), and TANGO (F) was observed in lung SCC. Original magnification, 400 fold. SCC: squamous cell carcinoma.](oncotarget-07-31137-g003){#F3}

Correlation between MIA gene family expression and clinicopathological features in cervical cancers {#s2_4}
---------------------------------------------------------------------------------------------------

The detailed immunohistochemical results of the 126 cervical cancers selected for the second cohort are summarized in Table [4](#T4){ref-type="table"}. Non-tumor cervical mucosal samples had negative or very weak *MIA* gene family expression, whereas 34.1% (43/126), 31% (39/126), and 30.2% (38/126) of cervical cancer cases exhibited cytoplasmic MIA, MIA2, and TANGO staining, respectively (Figure [4A--4D](#F4){ref-type="fig"}). Moreover, co-expression rate of MIA and MIA2, MIA and TANGO, MIA2 and TANGO, and all molecules were 13.5% (17/126), 10.3% (13/126), 12.7% (16/126), and 7.9% (10/126), respectively. In cervical cancers, increased MIA expression correlated strongly with the clinical stage (*P* = 0.0177), T classification (*P* = 0.0185), and lymph node metastasis (*P* = 0.0477). No obvious correlations were identified between the level of MIA and TANGO expression and tumor histological type; in contrast, the MIA2 expression levels increased from CIN3 (1/15, 6.7%) to invasive SCC (38/111, 34.2%; *P* = 0.0361; Figure [4B, 4C](#F4){ref-type="fig"}). TANGO overexpression was more frequent in cases with nodal metastasis (7/11, 63.6%) or distant metastasis than in those without metastasis (31/115, 27%; *P* = 0.0175). In addition, TANGO immunostaining was observed in 83.3% (5/6) of cases with distant metastasis and only 27.5% (33/120) of cases without distant metastasis (*P* = 0.0095). No significant difference was observed between *MIA* gene family expression and other clinicopathological features in cervical cancers.

###### Relationship between expression of MIA gene family and clinicopathological characteristics in cervical cancer

                                                 MIA      MIA2   TANGO                  
  ---------------------------------------------- -------- ------ -------- ---- -------- ----
  Age                                                                                   
   \< −60                                        38       14     37       15   39       13
   \> 60                                         45       29     50       24   49       25
   *P* value                                     0.1835          0.6999        0.3287   
  Histology[\*](#tfn_003){ref-type="table-fn"}                                          
   CIN3                                          11       4      14       1    10       5
   SCC                                           72       39     73       38   78       33
   *P* value                                     0.5777          0.0361        0.7704   
  HPV16 and/or 18                                                                       
   Positive                                      53       33     56       30   57       29
   Negative                                      33       10     31       9    31       9
   *P* value                                     0.1131          0.2147        0.2192   
  Clinical stage                                                                        
   0--I                                          35       14     39       10   34       15
   II                                            43       19     38       24   46       16
   III--IV                                       5        10     10       5    8        7
   *P* value                                     0.0177          0.1145        0.2861   
  T classification                                                                      
   Tis-T1                                        34       14     38       10   33       15
   T2                                            45       20     39       26   49       16
   T3--4                                         4        9      10       3    6        7
   *P* value                                     0.0185          0.0755        0.1087   
  Nodal metastasis                                                                      
   Negative                                      79       36     81       34   84       31
   Positive                                      4        7      6        5    4        7
   *P* value                                     0.0477          0.3135        0.0175   
  Distant metastasis                                                                    
   Negative                                      80       40     84       36   87       33
   Positive                                      3        3      3        3    1        5
   *P* value                                     0.4096          0.3725        0.0095   

Relationship between expression of MIA genefamily and parameters were calculated by Fischer\'s exact test or chi-square test. T classification and clinical stage were classified according to the TNM classification.

Histology: CIN3, cervical intraepithelial neoplasia 3; SCC, squamous cell carcinoma

![Expression of the *MIA* gene family in cervical cancer\
(**A, C--D**) Immunostaining of the *MIA* gene family in invasive SCC. MIA (A), MIA2 (C), and TANGO (D) expression were observed in the cytoplasm of invasive cervical SCC. (**B**) Cases with CIN3 showed no immunoreactivity of MIA2. Original magnification, 400 fold. SCC: squamous cell carcinoma.](oncotarget-07-31137-g004){#F4}

Gene expression of MIA gene family and secretion of MIA in esophageal, lung, and cervical cancers {#s2_5}
-------------------------------------------------------------------------------------------------

Next, we verified the expression of *MIA* family genes in cases with esophageal, lung, and cervical cancers. In malignancies, expression levels of *MIA*, *MIA2*, and *TANGO* were significantly higher than in non-tumorous specimens (Figure [5A](#F5){ref-type="fig"}). Moreover, the expression of *MIA* family genes was significantly associated with immunohistochemical grade in esophageal, lung, and cervical cancers (Figure [5B](#F5){ref-type="fig"}). Expression levels of *MIA* gene family in primary tumor and metastatic sites remained unchanged (data not shown).

![Gene expression and secretion of the *MIA* gene family in esophageal, lung, and cervical cancer\
(**A**) Expression of *MIA*, *MIA2*, and *TANGO* in esophageal, lung, and cervical cancer by real-time RT-PCR. Normal esophageal, lung, and cervical tissues were set as 1. Expression levels of MIA, MIA2, and TANGO in malignancies were higher than normal tissues. (**B**) Association of MIA, MIA2, or TANGO expression with immunohistochemical grade in cases with esophageal, lung, and cervical cancer. In malignancies, expression levels of each genes were well correlated with immunohistochemical grade. (**C**) Comparison of MIA levels with serum and primary tumor. Tumor expression levels of *MIA* were significantly correlated with those of serum secretion levels in esophageal, lung, and cervical cancer. Error bar, standard deviation (SD). RQ; relative quantification.](oncotarget-07-31137-g005){#F5}

Next, *MIA* gene family expression levels were compared between serum samples and tumor specimens. Serum secretion levels of MIA measured by enzyme-linked immunosorbent assay (ELISA) were well correlated with those of tumor expression levels quantified by quantitative (qRT-PCR) (Figure [5C](#F5){ref-type="fig"}).

Disease free survival analysis of esophageal, lung, and cervical cancers {#s2_6}
------------------------------------------------------------------------

Finally, we conducted a Kaplan--Meier survival analysis. We found that patients with ESCC whose samples exhibited positive MIA, MIA2, and TANGO immunostaining had significantly shorter disease-free survival intervals, compared to patients with negative expression (*P* \< 0.0001, *P* = 0.0135, and *P* = 0.0131, respectively; Figure [6A--6C](#F6){ref-type="fig"}). Among patients with lung cancer, those with MIA, MIA2, and TANGO-positive samples had a significantly worse disease free survival than did those with negative samples (*P* \< 0.0001, *P* \< 0.0001, and *P* = 0.0006, respectively; Figure [6D--6F](#F6){ref-type="fig"}). Furthermore, MIA (*P* \< 0.0001), MIA2 (*P* = 0.0144), and TANGO expression (*P* = 0.0151) were associated with a poor prognosis among patients with cervical cancer (Figure [6G--6I](#F6){ref-type="fig"}).

![Disease free survival curves of cancer patients, as calculated by Kaplan--Meier method\
(**A--C**) Disease free survival curves in ESCC cases. Disease free survival period was significantly shorter in patients with MIA (A), MIA2 (B), and TANGO (C) expression than in those with no expression. (**D--F**) Disease free survival curves in lung cancer cases. Cases with expression of MIA (D), MIA2 (E), and TANGO (F) had significantly worse prognosis than those with negative expression. (**G--I**) Disease free survival curves in cervical cancer cases. MIA (G), MIA2 (H), and TANGO (I) expression cases were correlated with poor prognosis. The *P*-value was calculated using the log-rank test.](oncotarget-07-31137-g006){#F6}

DISCUSSION {#s3}
==========

Although *MIA* gene family members serve several tumor-related functions, to our knowledge, this is the first report to subject a variety of human malignancies to semi-comprehensive immunohistochemical *MIA* gene family expression profiling. In this investigation, we found that *MIA* gene family members are frequently expressed in several types of human tumors, including SCCs. We also confirmed the significance of *MIA* gene family expression in ESCC, lung cancer, and cervical cancer. In particular, cases of ESCC and lung cancer with nodal and/or distant metastases were frequently positive for *MIA* gene family expression; similarly, lung SCCs were frequently positive for these proteins. In addition, *MIA* gene family expression was also associated with a poor prognosis among cancer patients. However, further research is needed to determine the association between *MIA* gene family expression and clinicopathological significance in tumors. TMA has recently become as powerful tool for large-scale expression analysis. TMA immunohistochemistry is a valuable high-throughput analysis technique because it eliminates technical variations among cases by subjecting all tissue cores to equal immunostaining conditions \[[@R24]\]. Additional immunohistochemical analyses of *MIA* gene family expression using large numbers of TMA slides will likely be effective.

In the present study, we have demonstrated the expression of MIA in previously uninvestigated tumors. Notably, MIA promotes cell detachment, migration, and invasion and suppresses cancer cell apoptosis and lymphokine activated killer cell (LAK) infiltration. In addition, MIA is a ligand for the cell surface receptors integrin α~4~β~1~/α~5~β~1~ and binds to fibronectin via SH3 domain-like structures to inhibit cell-to-stromal adhesion \[[@R9], [@R25], [@R26]\]. In a previous report, we described the activation of MIA via interactions of intracellular HMGB1 with NFkBp65 and observed the strong implication of MIA in tumor progression and nodal metastasis through the induction of angiogenesis and lymphangiogenesis in OSCC \[[@R17], [@R18]\]. MIA expression has also been observed in malignant melanoma, gastric cancer, pancreatic cancer, breast cancer, chondrosarcoma, glioma, and OSCC \[[@R7]--[@R12], [@R17], [@R18], [@R27]--[@R30]\].

Several reports have revealed that MIA2 and TANGO can act as tumor suppressors \[[@R4]--[@R6], [@R15]\]; it is therefore interesting that according to our current results and previous findings, MIA2 and TANGO might behave as proto-oncogenes in SCCs of the esophagus, lung, and cervix \[[@R19], [@R20]\]. These potential oncogenic roles might depend on receptor-related signaling differences. Indeed, we revealed that signaling through the MIA2-integrin α~5~β~1~-JNK pathway promotes apoptosis, whereas signaling through the MIA2-integrin α~4~β~1~-MAPK p38 pathway suppresses apoptosis \[[@R19]\]. Furthermore, MIA2 inhibits lymphocyte infiltration into tumors by binding integrin α~4~, thus dysregulating the host immune system \[[@R19]\]. Similar to MIA, MIA2 might also interact with fibronectin, which induces T lymphocyte chemotaxis when combined with stromal cell-derived factor 1α \[[@R31]\]; therefore, MIA or MIA2 might suppress T lymphocyte chemotaxis by masking fibronectin. TANGO expression is observed in many adult tissues \[[@R3]\]; we also confirmed weakly expression of TANGO in cancer-adjacent tissues (data not shown). In addition, we previously found that TANGO promotes tumor angiogenesis and lymphangiogenesis by activating PDGFB and neuropilin 2 \[[@R20]\]. Although TANGO is a ligand for CD11c/CD18 \[[@R5]\], we did not observe a direct interaction between TANGO and this receptor in OSCC cells \[[@R20]\]. More detailed studies will be needed to identify alternate receptors for TANGO in tumor cells; these might include other integrins or adhesion molecules.

In conclusion, we have demonstrated the utility of *MIA* gene family members as tumor markers, using a wide range of esophageal, lung, and cervical cancer samples. Although innumerable studies have investigated tumor biomarkers, the usefulness of molecular biomarkers for malignant tumors remains controversial. As *MIA* gene family members are secretory proteins \[[@R3]\], they might be detectable in serum, saliva, urine, ascites, pleural fluid, and other samples that can be collected more easily than tumors. Although additional detailed and large-scale examinations will be fundamental to determining the importance of *MIA* gene family members in cancers, our findings indicate that these proteins are alternative and efficacious diagnostic and treatment targets in human cancers. Our results therefore provide new knowledge about molecular tumor markers that could potentially improve the clinical outcomes and quality of life of affected patients.

MATERIALS AND METHODS {#s4}
=====================

Tissue specimens {#s4_1}
----------------

Randomly selected formalin-fixed, paraffin-embedded (FFPE) specimens were used for the present analysis. All FFPE samples were diagnosed at the Department of Molecular Pathology, Nara Medical University. To screen the expression of *MIA* family genes, we used a training cohort of 477 FFPE specimens in tumors of the following organs: 36 head and neck cancers, 15 salivary gland cancers, 10 esophageal cancers, 35 gastric cancers, 5 gastrointestinal tumors (GISTs) in the small intestine, 35 colorectal cancers, 16 liver cancers, 10 biliary cancers, 5 pancreatic cancers, 33 lung cancers, 33 bone and soft tissue malignant tumors, 3 skin malignant tumors, 19 breast cancers, 26 cervical cancers, 12 endometrial cancers, 47 ovarian cancers, 6 prostatic cancers, 11 testicular cancers, 17 bladder cancers, 16 kidney cancers, 15 thyroid cancers, 15 adrenal tumors, 20 malignant lymphomas, and 19 cancers of other tissues (Table [1](#T1){ref-type="table"}).

Additionally, the validation set of *MIA* gene family expression comprised FFPE esophageal cancer, cervical cancer, and lung cancer tissues. The details of specimens are as follows: 66 cases of ESCC (49 men and 17 women, age range: 47--80 years, mean age = 67.5 years), 145 cases of lung cancer (107 men and 38 women, age range: 45--83 years, mean age = 66.7 years), and 126 cases of cervical cancer (age range: 24--74 years, mean age = 59.2 years). The lung cancer cases were subclassified as follows: 105 squamous cell carcinomas (SCCs), 25 adenocarcinomas, 10 small cell carcinomas, and 10 large cell neuroendocrine carcinomas (LCNECs). The 126 cervical cancers included 15 cases of cervical intraepithelial neoplasia 3 (CIN3) and 111 of invasive SCC. Among all cases used for the validation set of *MIA* gene family expression by immunohistochemistry, frozen and serum samples were available for gene expression and ELISA from cases with 10 ESCC, 14 lung cancer, and 13 cervical cancer, respectively. Each 5 samples of normal esophageal, lung, and cervical tissue and serum in healthy donor were used for control.

No patient received preoperative therapy. Tumor staging was performed according to the Union for International Cancer Control TNM classification system (seventh edition), and tumor histology was classified according to the World Health Organization criteria. Because written informed consent was not obtained for the immunohistochemical analysis, any identifying information was removed from the samples before the analysis to ensure the strict protection of patient privacy (unlinkable anonymizing). Written informed consent was obtained from individual patients for the use of their samples in the gene expression analysis and ELISA. The study plan was performed according to the ethical standards proposed in the *Declaration of Helsinki* and was approved by the Medical Ethics Committee of Nara Medical University, Kashihara, Japan (approval number. 719).

Immunohistochemistry {#s4_2}
--------------------

Consecutive 3-μm sections were cut from each block and subjected to immunohistochemical staining with the EnVision+ DualLink system (DAKO, Carpinteria, CA, USA). After a 20-min antigen retrieval treatment with pepsin (DAKO), the sections underwent staining using an immunoperoxidase technique. Briefly, after a 15-min endogenous peroxidase block with 3% H~2~O~2~-methanol, specimens were incubated in a 10% skim milk solution (Morinaga Milk, Tokyo, Japan) for 20 min to block non-specific antibody reactions and rinsed 3 times with phosphate-buffered saline (PBS) (Sigma-Aldrich, St. Louis, MO, USA). Anti-MIA (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-MIA2 (Abcam, Tokyo, Japan), and anti-TANGO/MIA3 antibodies (LifeSpan, Seattle, WA, USA) were diluted to 1 μg/ml and used as primary antibodies; after a two hour primary antibody incubation, the sections were incubated with a secondary antibody for 30 minutes at room temperature. The specimens were subsequently rinsed three times with PBS and color-developed using a diaminobenzidine (DAB) solution (DAKO). After washing to remove excess DAB solution, the specimens were counterstained with Meyer\'s hematoxylin (Sakura Finetek Japan, Tokyo, Japan). All samples were immunostained under the same antibody reaction and DAB exposure conditions. Appropriate negative and positive control slides were used.

Evaluation of immunohistochemistry {#s4_3}
----------------------------------

MIA, MIA2, and TANGO immunoreactivities were classified according to the Allred\'s score (AS) \[[@R32]\]. We divided immunoreactivities into four grades based on AS: Grade 0, AS = 0; Grade 1, AS = 2--4; Grade 2, AS = 5--6; and Grade 3, AS = 7--8. Grade 2 and 3 cases were considered immunologically positive, in accordance with our previous report \[[@R33]\].

RNA extraction and qRT-PCR {#s4_4}
--------------------------

Total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and 1 mg of total RNA was converted to cDNA with a ReverTra Ace qPCR RT Kit (Toyobo, Osaka, Japan). Real-time RT- PCR was performed on a StepOnePlus Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) using TaqMan Fast Universal PCR Master Mix (Applied Biosystems), and analyzed using the relative standard curve quantification method. The PCR conditions used were selected according to the manufacturer\'s manual and *glyceraldehyde-3-phosphate dehydrogenase* (*GAPDH*) mRNA was amplified as an internal control. TaqMan Gene Expression Assays of *MIA*(Hs00197954_m1), *MIA2* (Hs00365015_m1), *MIA3* (*TANGO*) (Hs00412706_m1), and *GAPDH* (ID: Hs03929097_g1) were purchased from Applied Biosystems. All PCRs were performed in triplicate.

ELISA for MIA {#s4_5}
-------------

The serum samples were obtained before treatment and stored at −80°C. Serum levels of MIA were measured by ELISA system for MIA (Roche Diagnostics, Mannheim, Germany) according to the manufacturer\'s instructions. All samples were tested in triplicate.

Statistical analysis {#s4_6}
--------------------

Relationships between *MIA* gene family expression and clinicopathological parameters were calculated using the chi-square test or Fisher\'s exact test. Disease free survival was analyzed according to the Kaplan--Meier method, and differences between groups were calculated using a log-rank test. JMP8 software (SAS Institute, Cary, NC, USA) was used for all statistical analyses. *P* values \< 0.05 were considered statistically significant.
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